Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Pancreatic cancer is chemo-resistant and metastasizes early with an overall five-year survival of ∼8.2%. First-in-class imipridone ONC201 is a small molecule in clinical trials with anti-cancer activity. ONC212, a fluorinated-ONC201 analogue, shows preclinical efficacy in melanoma and hepatocellular...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Lev, Avital, Lulla, Amriti R., Wagner, Jessica, Ralff, Marie D., Kiehl, Joshua B., Zhou, Yan, Benes, Cyril H., Prabhu, Varun V., Oster, Wolfgang, Astsaturov, Igor, Dicker, David T., El-Deiry, Wafik S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2017
Schlagworte:
Priority Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669847/
https://ncbi.nlm.nih.gov/pubmed/29137221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20819
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge